Cubist Pharmaceuticals (CBST) Tops Q3 EPS Views
More News related to CBST
- The Boston Globe names Cubist to Globe 100's Top Places to Work '09
- Cubist Pharmaceuticals to Present at Lazard Capital Markets 6th Annual Healthcare Conference
- Oppenheimer Upgrades Cubist Pharmaceuticals (CBST) to Perform
- Hydra Biosciences and Cubist Form Collaboration to Develop Novel Ion Channel Drugs for Pain Management
- Cubist Pharmaceuticals (CBST) Tops Q3 EPS Views
More News related to Earnings
- Quicksilver Resources (KWK) Granted Motion for Partial Summary by Texas in BreitBurn (BBEP) Lawsuit
- American International Group (AIG) Implementing Benmosche's Compensation Agreement
- Sun American (SAMB) Receives Listing Rule 5450 Notification from NASDAQ
- Solutia (SOA) To Discontinue Manufacturing at its Plant in Cologne, Germany
- General Dynamics (GD) Business Unit Awarded $2.2B U.S. Army SAC Contract for 724 LAV's
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) reports Q3 EPS of $0.42, or $0.65 non-GAAP, 9 better than the analyst estimate of $0.33. Revenue rose 28% to $143.5 million, which compares to the estimate of $142.12 million.
Related Categories
EarningsStocks Mentioned
-0.19Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
